Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

30 Oct 2007 10:02

ViaLogy PLC30 October 2007 30 October 2007 ViaLogy plc AGM statement At the Annual General Meeting of ViaLogy PLC (VIY), the AIM-quoted technologycompany that is a leading innovator of network-centric, real time signalprocessing platforms for sensor applications, to be held at 10am today, theChairman, Terry Bond, will make the following statement. "It has been a year since shareholders approved the acquisition of the remainderof ViaLogy's share capital and the change of name to ViaLogy plc. During theyear the company has achieved a number of significant technical and productmilestones and the transition from research and development-driven activities tothe commercialisation of the technology is well underway. Over the next year ViaLogy will roll-out several products, principally SPM,MicroSPM and MPEX, initially targeting the defence, oil & gas and enterprisemarkets. These applications are based on ViaLogy's proprietary,patent-protected Quantum Resonance Interferometry (QRI) signal processingtechnology that enables the detection and interpretation of very weak signalsfrom large amounts of information and background noise. Ultimately SPM providesa solution to the problem of sensor integration. SPM, Sensor Policy Manager, is an enterprise-grade software product for sensorprocessing and interoperability. Unlike other sensor management solutions thatwork only with sensors from a single vendor, ViaLogy SPM software automaticallydiscovers network-attached sensors from any vendor, fuses and normalises theirinputs for central monitoring, and invokes real-time actions based oncustomer-defined policies. The network-centric approach provides measurablebenefits for security, safety and surveillance. The technology can integrate upto thousands of sensors connected to wireless and wired networks without delaysor loss of coverage. One of the early adopters of the SPM technology was Cisco Systems, which hasimplemented the technology at its San Jose campus to support safety and securityoperations, enabling the automation of complex facility operations. ViaLogy hasalso negotiated contracts for further SPM installations in the US and Taiwan. MicroSPM, is a compact, hardware-based solutions for real-time video and sensordata processing. It is designed to automate and improve the speed andeffectiveness of security and surveillance activities, such as face recognitionin crowds; human, object and vehicle detection and counting; and license platereading, in particular under difficult environment conditions. Reducingreliance on multiple human operators for analysis and decision-making. MPEX (Multi Parallax Exploitation) Electronic Eye, is a major advancement incomputer vision and video surveillance technology. In development with BoeingPhantom Works, the electronic eye is capable of 360 degree video processing,based on bionic principles that mimic the optical movements of some insects andreptiles. Initial applications for this technology will be for the detection ofvery fast moving targets such as missile interceptors, deployment of fast movingground vehicles and airborne platforms like unmanned aerial vehicles. Beyond these products other opportunities exist for ViaLogy's technology asannounced during the year. A technical breakthrough to improve the stability andperformance of miniature vibratory gyroscopes, achieved in collaboration withNASA's Jet Propulsion Laboratory and Boeing, which has wider applications in theemerging Micro Electro-Mechanical Systems (MEMS) market; the development of thedual-beam Reverse Photo-Acoustic Spectrometer (REPAS) with the Oak RidgeNational Laboratory for the detection of chemical, biological, radiological,nuclear and explosive materials; and, selection by the US Department of Defenseto provide a command and control platform for joint experiments to support thenext generation Joint Force Protection Advanced Security (JFPASS). An investment is being made to establish a strong sales and marketing team inorder for the Company to be able to exploit the opportunities available to it bybuilding relationships with potential partners and identifying global saleschannels. As you can see it is an exciting time for ViaLogy and the Board is enthusiasticand confident about the progress the Company will make over the next year andbeyond." End For further information please contact: ViaLogyTerry Bond, Chairman +44 (0)1235 834734 or 07860 842756Seymour Pierce Mark Percy, Nominated Adviser +44 (0)20 7107 8000Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0)20 7822 0200 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications. ViaLogy is currently deploying and designingcomputational systems, powered by its patented technologies, for applications inlife sciences, public safety and security, surveillance, defence andgeoseismology. Vialogy focuses on market driven problems where automation,timeliness, quality and reliability of information processing are essential.ViaLogy's core competency incorporates rapidly and accurately detecting weaksignals buried in high noise background and clutter. This technology can beemployed to solve problems involving sensor integration and information overloadchallenges involving video, telephony and control sensors, as well as forenhancement of numerous signal processing applications. For more information,visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Nov 20207:00 amRNSDirectorate Change
3rd Nov 20207:00 amRNSPartnership with Take2 Health Limited
26th Oct 20207:00 amRNSHalf-year Trading update
23rd Oct 20207:00 amRNSCQC accreditation
21st Oct 20207:00 amRNSYourgene Genomic Services collaboration with Cytox
12th Oct 20207:00 amRNSElucigene DPYD tests to be used routinely in Wales
8th Oct 20207:00 amRNSStrategic reproductive health partnership in Japan
7th Oct 20207:00 amRNSIONA®Nx awarded contract with St George’s Hospital
5th Oct 20207:00 amRNSShare Incentive Plan
1st Oct 20204:59 pmRNSCorrection: Holding(s) in Company
1st Oct 20203:29 pmRNSHolding(s) in Company
28th Sep 20207:00 amRNSLaunch of Yourgene Genomic Services
25th Sep 20205:28 pmRNSIssue of Share Options
24th Sep 202010:00 amRNSDPD reimbursement in Germany
24th Sep 20207:00 amRNSDirector/PDMR Shareholding
23rd Sep 20205:20 pmRNSExercise of Options
23rd Sep 202012:25 pmRNSDirector/PDMR Shareholding
22nd Sep 20205:14 pmRNSResult of AGM
22nd Sep 20207:00 amRNSAGM Statement
21st Sep 20207:00 amRNSUS distribution agreement for DPYD &other products
9th Sep 20207:00 amRNSAGM update and investor presentation
3rd Sep 20207:00 amRNSIONA® Nx Launch
28th Aug 20207:00 amRNSNotice of AGM & Annual Report 2020
13th Aug 20207:00 amRNSTGA approves IONA® Nx for sale in Australia
11th Aug 20207:00 amRNSAdmission of Company Considerations Shares and TVR
7th Aug 20203:42 pmRNSHolding(s) in Company
7th Aug 20203:25 pmRNSHolding(s) in Company
7th Aug 20209:48 amRNSHolding(s) in Company
5th Aug 20201:15 pmRNSResult of Placing
5th Aug 20207:00 amRNS£16.15m Placing & Close of Accelerated Bookbuild
4th Aug 20205:13 pmRNSProposed Acquisition and Placing
3rd Aug 20207:00 amRNSCE-IVD Mark for Clarigene™ SARS-CoV-2 test
29th Jul 202012:05 pmRNSAppointment of Joint Broker
28th Jul 20207:00 amRNSFinal Results
13th Jul 20201:13 pmRNSNotice of Results
30th Jun 20207:00 amRNSCOVID-19 assay launched
19th Jun 20204:44 pmRNSIssue of Share Options
16th Jun 20207:00 amRNSCollaboration in COVID-19 testing
15th Jun 20207:00 amRNSCE-IVD mark received for Illumina-based IONA® test
26th May 202012:00 pmRNSHolding(s) in Company
26th May 20207:00 amRNSCOVID-19 testing service launch; business update
20th May 20207:00 amRNSExercise of Warrants and Options
20th Apr 20207:00 amRNSYear-end Trading update: Revenues increase 86%
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:36 pmRNSPrice Monitoring Extension
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSPresentation on ‘Adapting during crisis’

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.